Pantoprazole sodium - CAS 138786-67-1
Catalog number: 138786-67-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Proton Pump
The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal reflux through influencing gastric acid secretion.
White to off-white solid
Pantoloc; Pantoprazole (sodium); Pantoprazole Sodium; Protonix IV; Protonix delayed-release; Pantoprazole Sodium [USAN]
H2O: ≥ 35 mg/mL
-20ºC Freeze
The sodium salt form of Pantoprazole is a gastic proton pump inhibitor that could be used in the treatment of ulceration and some diseases induced by gastroesophageal reflux through influencing gastric acid secretion.
Quality Standard:
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
1.Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase.
Zeng X1, Liu L1, Zheng M2, Sun H3, Xiao J1, Lu T1, Huang G1, Chen P4, Zhang J1, Zhu F1, Li H2,5, Duan Q1. Oncotarget. 2016 Mar 8. doi: 10.18632/oncotarget.7984. [Epub ahead of print]
T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor. Pantoprazole (PPZ) was identified to be a TOPK inhibitor from FDA-approved drug database by structure based virtual ligand screening. Herein, the data indicated that pantoprazole inhibited TOPK activities by directly binding with TOPK in vitro and in vivo. Ex vivo studies showed that pantoprazole inhibited TOPK activities in JB6 Cl41 cells and HCT 116 colorectal cancer cells. Moreover, knockdown of TOPK in HCT 116 cells decreased their sensitivities to pantoprazole. Results of an in vivo study demonstrated that i.p. injection of pantoprazole in HCT 116 colon tumor-bearing mice effectively suppressed cancer growth. The TOPK downstream signaling molecule phospho-histone H3 in tumor tissues was also decreased after pantoprazole treatment. In short, pantoprazole can suppress growth of colorectal cancer cells as a TOPK inhibitor both in vitro and in vivo.
2.Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
Petryszyn P1, Staniak A1, Grzegrzolka J2. J Comp Eff Res. 2016 Mar;5(2):169-78. doi: 10.2217/cer.15.63. Epub 2016 Mar 7.
OBJECTIVES: To compare the cost-effectiveness of therapy of gastroesophageal reflux disease with esomeprazole and other proton pump inhibitors (PPIs) in Poland.
3.Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A1, Emrence Z, Baran B, Gokturk S, Soyer OM, Evirgen S, Akyuz F, Karaca C, Besisik F, Kaymakoglu S, Ustek D, Demir K. Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):879-85.
OBJECTIVE: Cytochrome P450 2C19 (CYP2C19) polymorphisms play an important role in the metabolism of proton pump inhibitors. Rabeprazole is primarily metabolized via non-enzymatic pathways. In this study, we determined whether rabeprazole- and pantoprazole-based eradication treatments were influenced by CYP2C19 polymorphisms.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products

CAS 335299-59-7 Tenatoprazole sodium

Tenatoprazole sodium
(CAS: 335299-59-7)

Tenatoprazole is a novel proton pump inhibitor which is similar to the chemical structure of omeprazole, a widely used proton pump inhibitor. Tenatoprazole belo...

Esomeprazole magnesium salt
(CAS: 1198768-91-0)

The magnesium salt form of Esomeprazole which is a proton pump inhibitor so that could be probably useful in the treatment of sorts of digestive tract diseases ...

CAS 73590-58-6 Omeprazole

(CAS: 73590-58-6)

Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...

CAS 138530-94-6 Dexlansoprazole

(CAS: 138530-94-6)

Dexlansoprazole is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux dis...

CAS 138786-67-1 Pantoprazole sodium

Pantoprazole sodium
(CAS: 138786-67-1)

The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal...

CAS 117976-89-3 Rabeprazole

(CAS: 117976-89-3)

Rabeprazole, a partially reversible inhibitor of gastric proton pump, could be used in the treatment of sorts of gastrointestinal disease especially peptic ulce...

CAS 161796-84-5 Esomeprazole potassium

Esomeprazole potassium
(CAS: 161796-84-5)

Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorat...

Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

Chemical Structure

CAS 138786-67-1 Pantoprazole sodium

Quick Inquiry

Verification code

Featured Items